OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Drug Safety is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)	39
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study	32
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada	25
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community	22
Adverse drug reactions associated with glycyrrhiza-containing Chinese patent medicines: a literature-based analysis of individual case reports and clinical trials	22
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study	21
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions	19
Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study	17
Methotrexate use and risk of abnormal alanine aminotransferase elevation in children with rare inflammatory diseases: a self-controlled case series analysis using a pediatric electronic health record	16
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana	15
Adverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System	14
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database	14
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend	14
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging	12
Machine learning risk prediction models for medication harm in hospitalised adult patients	12
Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling	11
Prevalence of potentially inappropriate medication use and its association with hospitalization among older adults with chronic disease in the Amhara region, Ethiopia: a multicenter prospective cohort	11
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis	10
Disparities and trends in drug-related adverse reaction mortality in the United States, 1999–2020	10
Complex chronic adverse events following immunization: a systemic critique and reform proposal for vaccine pharmacovigilance	10
The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology	9
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review	9
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences	9
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study	9
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study	9

Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey	9
Data mining results for reduction of adverse drug–drug interaction events in older adults are clinically applicable	8
The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey	8
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction	8
Impact of risk communication on patient’s safety during the pandemic	7
Drug recall, its frequencies and conclusion: a retrospective secondary analysis involving 2-year publicly available data from Nepal	7
Impact of social determinants of health on safety of patients in device clinical trials conducted at a safety-net hospital	7
Artificial intelligence in drug development: reshaping the therapeutic landscape	7
Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer	7
Treating hearts and minds: adverse cardiovascular effects of psychiatric medications	7
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System	6
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers	6
Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study	6
Flow rate accuracy of infusion devices within healthcare settings: a systematic review	6
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database	6
Probable case of anaphylaxis due to hydrocortisone in a septic shock patient	6
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system	6
Efficacy and safety of ciprofol versus propofol for sedation in hysteroscopy: a systematic review and meta-analysis	6
Machine learning studies of drug-induced nephrotoxicity: a scoping review	6
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations	6
A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts	6
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward	6